253 related articles for article (PubMed ID: 30904971)
41. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
43. Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments.
Su P; Wang J; Shi Y; Pan X; Shao R; Zhang J
Bioorg Med Chem; 2015 Jul; 23(13):3228-36. PubMed ID: 25982075
[TBL] [Abstract][Full Text] [Related]
44. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
45. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
Shi L; Zhou J; Wu J; Cao J; Shen Y; Zhou H; Li X
Bioorg Med Chem; 2016 Apr; 24(8):1840-52. PubMed ID: 26968648
[TBL] [Abstract][Full Text] [Related]
46. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
47. Discovery of potent vascular endothelial growth factor receptor-2 inhibitors.
Papakyriakou A; Katsarou ME; Belimezi M; Karpusas M; Vourloumis D
ChemMedChem; 2010 Jan; 5(1):118-29. PubMed ID: 19921722
[TBL] [Abstract][Full Text] [Related]
48. In silico insights into design of novel VEGFR-2 inhibitors: SMILES-based QSAR modelling, and docking studies on substituted benzo-fused heteronuclear derivatives.
Gupta S; Kashyap M; Bansal Y; Bansal G
SAR QSAR Environ Res; 2024 Apr; 35(4):265-284. PubMed ID: 38591137
[TBL] [Abstract][Full Text] [Related]
49. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834
[TBL] [Abstract][Full Text] [Related]
50. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
51. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.
Sun H; Zhuo L; Dong H; Huang W; She N
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817456
[TBL] [Abstract][Full Text] [Related]
52. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
53. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
55. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
56. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
[TBL] [Abstract][Full Text] [Related]
57. Virtual Screening, Docking, and Designing of New VEGF Inhibitors as Anti-cancer Agents.
Patel S; Singh VR; Suman AK; Jain S; Sen AK
Curr Drug Discov Technol; 2024; 21(1):e101023222024. PubMed ID: 38629172
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
59. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
[TBL] [Abstract][Full Text] [Related]
60. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
Kumar R; Garg P; Bharatam PV
J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]